Markets

TrueBlue refutes EHS Management’s claims, highlighting its successful strategic execution and board refreshment. The company asserts its current plan is driving improved financial results and profitable growth, making external shareholder action unnecessary. TrueBlue has proactively engaged with EHS, informing them of board changes prior to their public announcement and selected new directors for their superior expertise. The company regrets EHS’s pursuit of a costly proxy contest amidst ongoing positive transformation.

Mike Lindell Media Corp. plans an expanded 2026 media presence with enhanced Washington D.C. coverage and significant upgrades to LindellTV and VOCL. The conservative alternative to mainstream media will feature dedicated reporting from the White House, Capitol Hill, and the Pentagon. New programming and a redesigned digital platform with a news aggregation system are being introduced. VOCL Studio and a live streaming feature will empower content creators and influencers, offering an uncensored broadcasting option. The company aims to provide “the truth and a voice like never before” to its audience.

Crown Holdings will release its Q4 and full-year 2025 results on February 4, 2026, followed by an investor call. Analysts will focus on the packaging giant’s performance across its markets, its response to inflation and supply chain issues, and its strategies for specialty packaging and sustainability initiatives. Crown Holdings’ outlook on innovation and its global expansion will also be key discussion points.

Easy Environmental Solutions (EZES) is accelerating global expansion in 2026, moving from technology validation to large-scale deployment of sustainable agriculture and water solutions. The company is integrating its Terreplenish® microbial soil solution with NanoVoid™ water treatment technology. With significant progress in Africa, the Middle East, and Europe, EZES aims to become a leading provider of integrated, cost-effective sustainability infrastructure worldwide, addressing food security and water scarcity challenges.

Antanas Guoga has increased his stake in Sol Strategies to nearly 20% through a debt settlement. This move converts debt into equity, boosting insider ownership and potentially optimizing the company’s balance sheet. Guoga may engage in further transactions, indicating an active investment approach. While the stock shows stable trading interest, it remains below its 200-day moving average. Recent operational news has yielded mixed market reactions, with a notable price drop following the VanEck Solana ETF staking provider announcement.

Silver X Mining reported strong 4Q25 production growth at its Peruvian property, driven by a 24% increase in processed material and a 17% rise in silver equivalent ounces. Gold production also surged by 67%. These improvements stem from expanded capacity and enhanced operational efficiencies, positioning the company for sustained growth and value creation.

Myriad Uranium plans to acquire Rush Rare Metals in a merger, aiming for full control of the Copper Mountain Uranium Project in Wyoming. This strategic move, detailed in an updated LOI, offers Rush shareholders a premium. Rush’s Boxi property will be spun out into a new entity. Myriad, already holding a 75% stake, believes consolidated ownership will enhance project value, streamline operations, and capitalize on renewed global interest in domestic uranium supply.

UTStarcom has launched the SkyFlux SPN310, a compact, fanless router designed to enhance its metro and enterprise edge offerings. With 16 Gbps switching capacity and 10GE support, it’s ideal for SMEs, 5G transport, and aggregation networks. Its dual-mode firmware allows deployment with SkyFlux or NetRing platforms, broadening market reach and offering cost-effective upgrades for existing clients.

Organon has partnered with Daiichi Sankyo Europe to distribute Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland, and Norway. This collaboration aims to increase patient access to Nilemdo®, a novel treatment for high cholesterol and cardiovascular disease risk, especially for those intolerant to statins. Organon will handle distribution and promotion, supporting its cardiovascular portfolio and addressing unmet patient needs, particularly for women who often experience statin intolerance.

Arrowhead Pharmaceuticals successfully raised $625 million through convertible notes and common stock offerings. This substantial capital infusion will fund pipeline development, operations, and potential product launches. The offerings include 0.00% convertible senior notes due 2032 and common stock, with underwriters having options to purchase additional securities. The company also utilized capped call transactions to mitigate potential dilution from note conversions. Proceeds will support R&D, clinical trials, and general corporate purposes.